Fig. 3From: Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysisCRi of patients with TP53m AML treated with IC (A), HMA (B), or VEN + HMA (C). AML, acute myeloid leukemia; CI confidence interval; CR, complete remission; CRi, CR with incomplete hematologic recovery; HMA, hypomethylating agent; IC, intensive chemotherapy; TP53m, TP53-mutated; VEN, venetoclaxBack to article page